
Jimmy Gårdebrink is an Associate Principal based in RBB’s Stockholm office. He has extensive experience in merger assessment, having worked on having worked on many in-depth Phase II investigations raising horizontal, vertical and conglomerate concerns. He has also advised on a wide variety of other matters, including abuse of dominance cases, anticompetitive agreements, cartel investigations and follow-on damages litigations.
Jimmy has advised clients on a variety of competition matters, including merger control and abuse of dominance before the European Commission and the national competition authorities in Scandinavia and in Europe. He has also provided economic advice during private enforcement proceedings, including cartel damage cases.
As a Swedish national, Jimmy is fluent in Swedish and English. Jimmy has significant experience working before the Swedish competition authority.
Prior to joining RBB in 2019, Jimmy worked for several years as a competition economist in private practice.
In addition, Jimmy has advised national regulators and private clients on market regulation. He has experience giving economic advice to clients in the telecom industry and the postal industry. Regulatory work includes the design of price cap, access regulation and evaluating the scope of a universal service.
His industry experience includes postal services, trucks, telecom, insurance, security, digital platforms, transportation.
Jimmy holds a MSc in Economics from the Copenhagen Business School and a BSc in Economics from Uppsala University.
Selected Cases
-
Apoteksgruppen/Aptek Kronan
Merger, Sweden
-
Swedavia
State aid, Sweden
-
European Commission
Ex-post evaluation of mergers, European Commission
-
Axfood/Bergendahls
Merger, Sweden
-
BEWI/Jackon
Merger, Nordics
-
Willis Tower Watson/Aon
Merger, Global
-
DIC group/BASF Colors & Effects
Merger, EU & Japan
-
Confidential
Follow-on damages & Abuse of dominance, Sweden
A global network of experienced experts
Our 230-strong, multi-lingual team, spread across 16 offices, has managed over 3,000 cases in 120+ countries, advising on more than one-third of EU Phase II cases in the last 5 years.

